Menarini withdraws EU filing of antibiotic Factive
This article was originally published in Scrip
Executive Summary
Menarini and Oscient Pharmaceuticals have withdrawn the EU marketing application of quinolone antibacterial Factive (gemifloxacin) 320mg film-coated tablets for the treatment of community-acquired pneumonia (CAP), acute bacterial exacerbations of chronic bronchitis (AECB) and acute bacterial sinusitis.